Diagnosis of monoclonal gammopathy of renal significance

Kidney International

Volumn 87, Issue 4, 2015, Pages 698-711

  Bridoux, Frank ^a   Leung, Nelson ^b   Hutchison, Colin A ^c   Touchard, Guy ^a   Sethi, Sanjeev ^b   Fermand, Jean Paul ^d   Picken, Maria M ^e   Herrera, Guillermo A ^f   Kastritis, Efstathios ^g   Merlini, Giampaolo ^h   Roussel, Murielle ⁱ   Fervenza, Fernando C ^b   Dispenzieri, Angela ^b   Kyle, Robert A ^b   Nasr, Samih H ^b  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d SAINT LOUIS HOSPITAL   (France)

^e LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^f Louisiana State University Health Sciences Center at Shreveport   (United States)

^g UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^h UNIVERSITY OF PAVIA   (Italy)

ⁱ CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN M; PARAPROTEIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN LIGHT CHAIN;

AMYLOIDOSIS; BLOOD EXAMINATION; C3 GLOMERULONEPHROPATHY; COMPLEMENT FIXATION; DISEASE SEVERITY; EARLY DIAGNOSIS; ELECTRON MICROSCOPY; GLOMERULONEPHRITIS; HUMAN; IMMUNE COMPLEX NEPHRITIS; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN DEPOSITION; IMMUNOTACTOID GLOMERULOPATHY; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; LIGHT CHAIN PROXIMAL TUBULOPATHY; MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE OF THE RANDALL TYPE; MONOCLONAL IMMUNOGLOBULINEMIA; MONOCLONAL IMMUNOGLOBULINEMIA OF RENAL SIGNIFICANCE; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PROTEOMICS; REVIEW; TYPE I CRYOGLOBULINEMIC GLOMERULONEPHRITIS; ALGORITHM; BIOPSY; BLOOD; COMPLICATION; KIDNEY; KIDNEY DISEASES; METABOLISM; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; PATHOLOGY; URINE;

ALGORITHMS; BIOPSY; HEMATOLOGIC TESTS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOGLOBULINS; KIDNEY; KIDNEY DISEASES; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE;

EID: 84926520891     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.408     Document Type: Review

References (92)

1. Solomon A, Weiss DT, Kattine AA. Nephrotoxic potential of Bence Jones proteins. N Engl J Med 1991; 324: 1845-1851.
2. Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 1990; 150: 1693-1695.
3. Drayson M, Begum G, Basu S et al. Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood 2006; 108: 2013-2019.
4. Morel-Maroger L, Basch A, Danon F et al. Pathology of the kidney in Waldenstrom's macroglobulinemia. Study of sixteen cases. N Engl J Med 1970; 283: 123-129.
5. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006; 108: 2520-2530.
6. Kourelis TV, Kumar SK, Gertz MA et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol 2013; 31: 4319-4324.
7. Nasr SH, Valeri AM, Cornell LD et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol 2012; 7: 231-239.
8. Kyle RA, Durie BG, Rajkumar SV et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010; 24: 1121-1127.
9. Pozzi C, D'Amico M, Fogazzi GB et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis 2003; 42: 1154-1163.
10. Leung N, Bridoux F, Hutchison CA et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 2012; 120: 4292-4295.
11. Jaccard A, Moreau P, Leblond V et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007; 357: 1083-1093.
12. Fermand JP, Bridoux F, Kyle RA et al. How I treat monoclonal gammopathy of renal significance (MGRS). Blood 2013; 122: 3583-3590.
13. Leung N, Dispenzieri A, Fervenza FC et al. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis. Am J Kidney Dis 2005; 46: 270-277.
14. Lorenz EC, Gertz MA, Fervenza FC et al. Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant 2008; 23: 2052-2057.
15. Bridoux F, Hugue V, Coldefy O et al. Fibrillary glomerulonephritis and immunotactoid (microtubular) glomerulopathy are associated with distinct immunologic features. Kidney Int 2002; 62: 1764-1775.
16. Guiard E, Karras A, Plaisier E et al. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab. Clin J Am Soc Nephrol 2011; 6: 1609-1616.
17. Pinney JH, Lachmann HJ, Bansi L et al. Outcome in renal Al amyloidosis after chemotherapy. J Clin Oncol 2011; 29: 674-681.
18. Czarnecki PG, Lager DJ, Leung N et al. Long-term outcome of kidney transplantation in patients with fibrillary glomerulonephritis or monoclonal gammopathy with fibrillary deposits. Kidney Int 2009; 75: 420-427.
19. Leung N, Lager DJ, Gertz MA et al. Long-term outcome of renal transplantation in light-chain deposition disease. Am J Kidney Dis 2004; 43: 147-153.
20. Nasr SH, Sethi S, Cornell LD et al. Proliferative glomerulonephritis with monoclonal IgG deposits recurs in the allograft. Clin J Am Soc Nephrol 2011; 6: 122-132.
21. Pinney JH, Lachmann HJ, Sattianayagam PT et al. Renal transplantation in systemic amyloidosis-importance of amyloid fibril type and precursor protein abundance. Am J Transplant 2013; 13: 433-441.
22. Zand L, Lorenz EC, Cosio FG et al. Clinical Findings, Pathology, and Outcomes of C3GN after Kidney Transplantation. J Am Soc Nephrol 2013.
23. Sanada S, Ookawara S, Karube H et al. Marked recovery of severe renal lesions in POEMS syndrome with high-dose melphalan therapy supported by autologous blood stem cell transplantation. Am J Kidney Dis 2006; 47: 672-679.
24. Meri S, Koistinen V, Miettinen A et al. Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis. J Exp Med 1992; 175: 939-950.
25. Jokiranta TS, Solomon A, Pangburn MK et al. Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J Immunol 1999; 163: 4590-4596.
26. Debiec H, Hanoy M, Francois A et al. Recurrent membranous nephropathy in an allograft caused by IgG3kappa targeting the PLA2 receptor. J Am Soc Nephrol 2012; 23: 1949-1954.
27. Nasr SH, Satoskar A, Markowitz GS et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol 2009; 20: 2055-2064.
28. Kyle RA, Gertz MA, Greipp PR et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336: 1202-1207.
29. Palladini G, Dispenzieri A, Gertz MA et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012; 30: 4541-4549.
30. Venner CP, Lane T, Foard D et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012; 119: 4387-4390.
31. Picken MM. Amyloidosis-where are we now and where are we heading? Arch Pathol Lab Med 2010; 134: 545-551.
32. Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood 2013; 121: 5124-5130.
33. Lachmann HJ, Booth DR, Booth SE et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002; 346: 1786-1791.
34. Said SM, Sethi S, Valeri AM et al. Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis. Kidney Int 2014; 86: 370-377.
35. Said SM, Sethi S, Valeri AM et al. Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol 2013; 8: 1515-1523.
36. Fish R, Pinney J, Jain P et al. The incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies. Clin J Am Soc Nephrol 2010; 5: 1977-1980.
37. Leung N, Gertz M, Kyle RA et al. Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathyrelated kidney diseases. Clin J Am Soc Nephrol 2012; 7: 1964-1968.
38. Bridoux F, Sirac C, Hugue V et al. Fanconi's syndrome induced by a monoclonal Vkappa3 light chain in Waldenstrom's macroglobulinemia. Am J Kidney Dis 2005; 45: 749-757.
39. Messiaen T, Deret S, Mougenot B et al. Adult Fanconi syndrome secondary to light chain gammopathy. Clinicopathologic heterogeneity and unusual features in 11 patients. Medicine 2000; 79: 135-154.
40. Eirin A, Irazabal MV, Gertz MA et al. Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney. Nephrol Dia Transplant 2012; 27: 1097-1101.
41. Sicard A, Karras A, Goujon JM et al. Light chain deposition disease without glomerular proteinuria: a diagnostic challenge for the nephrologist. Nephrol Dial Transplant 2014; 29: 1894-1902.
42. Katzmann JA, Kyle RA, Benson J et al. Screening panels for detection of monoclonal gammopathies. Clin Chem 2009; 55: 1517-1522.
43. Palladini G, Russo P, Bosoni T et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 2009; 55: 499-504.
44. Anderson KC, Alsina M, Bensinger W et al. NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw 2009; 7: 908-942.
45. Dispenzieri A, Kyle R, Merlini G et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23: 215-224.
46. Sethi S, Zand L, Leung N et al. Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. Clin J Am Soc Nephrol 2010; 5: 770-782.
47. Bradwell AR, Carr-Smith HD, Mead GP et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47: 673-680.
48. Davern S, Tang LX, Williams TK et al. Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies. Am J Clin Pathol 2008; 130: 702-711.
49. Campbell JP, Cobbold M, Wang Y et al. Development of a highly-sensitive multi-plex assay using monoclonal antibodies for the simultaneous measurement of kappa and lambda immunoglobulin free light chains in serum and urine. J Immunol Methods 2013; 391: 1-13.
50. Nakano T, Nagata A. ELISAs for free human immunoglobulin light chains in serum: improvement of assay specificity by using two specific antibodies in a sandwich detection method. J Immunol Methods 2004; 293: 183-189.
51. te Velthuis H, Knop I, Stam P et al. N Latex FLC-new monoclonal highperformance assays for the determination of free light chain kappa and lambda. Clin Chem Lab Med 2011; 49: 1323-1332.
52. Hutchison CA, Harding S, Hewins P et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1684-1690.
53. Hutchison CA, Plant T, Drayson M et al. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol 2008; 9: 11.
54. Palladini G, Dispenzieri A, Gertz MA et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012; 30: 4541-4549.
55. Touchard G. Ultrastructural pattern and classification of renal monoclonal immunoglobulin deposits. In: Touchard G, Aucouturier P, Hermine O, Ronco P (eds) Monoclonal gammopathies and the kidney. Kluwer Academic Publishers: Dordrecht ; Boston, 2003 pp 95-120.
56. Gu X, Herrera GA. Light-chain-mediated acute tubular interstitial nephritis: a poorly recognized pattern of renal disease in patients with plasma cell dyscrasia. Arch Pathol Lab Med 2006; 130: 165-169.
57. Jain D, Green JA, Bastacky S et al. Membranoproliferative glomerulonephritis: the role for laser microdissection and mass spectrometry. Am J Kidney Dis 2014; 63: 324-328.
58. Nasr SH, Said SM, Valeri AM et al. The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int 2013; 83: 463-470.
59. Picken MM. Modern approaches to the treatment of amyloidosis: the critical importance of early detection in surgical pathology. Adv Anat Pathol 2013; 20: 424-439.
60. Howie AJ, Brewer DB. Optical properties of amyloid stained by Congo red: history and mechanisms. Micron 2009; 40: 285-301.
61. Shiiki H, Shimokama T, Yoshikawa Y et al. Renal amyloidosis. Correlations between morphology, chemical types of amyloid protein and clinical features. Virchows Arch A Pathol Anat Histopathol 1988; 412: 197-204.
62. Picken MM. Immunoglobulin light and heavy chain amyloidosis AL/AH: renal pathology and differential diagnosis. Contrib Nephrol 2007; 153: 135-155.
63. Sethi S, Vrana JA, Theis JD et al. Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis. Kidney Int 2012; 82: 226-234.
64. Sethi S, Theis JD, Vrana JA et al. Laser microdissection and proteomic analysis of amyloidosis, cryoglobulinemic GN, fibrillary GN, and immunotactoid glomerulopathy. Clin J Am Soc Nephrol 2013; 8: 915-921.
65. Herrera GA, Turbat-Herrera EA. Ultrastructural immunolabeling in the diagnosis of monoclonal light-and heavy-chain-related renal diseases. Ultrastruct Pathol 2010; 34: 161-173.
66. Nasr SH, Valeri AM, Cornell LD et al. Fibrillary glomerulonephritis: a report of 66 cases from a single institution. Clin J Am Soc Nephrol 2011; 6: 775-784.
67. Rosenstock JL, Markowitz GS, Valeri AM et al. Fibrillary and immunotactoid glomerulonephritis: distinct entities with different clinical and pathologic features. Kidney Int 2003; 63: 1450-1461.
68. Nasr SH, Fidler ME, Cornell LD et al. Immunotactoid glomerulopathy: clinicopathologic and proteomic study. Nephrol Dial Transplant 2012; 27: 4137-4146.
69. Terrier B, Karras A, Kahn JE et al. The spectrum of type I cryoglobulinemia vasculitis: new insights based on 64 cases. Medicine (Baltimore) 2013; 92: 61-68.
70. Nasr SH, Markowitz GS, Reddy BS et al. Dysproteinemia, proteinuria, and glomerulonephritis. Kidney Int 2006; 69: 772-775.
71. Karras A, Noel LH, Droz D et al. Renal involvement in monoclonal (type I) cryoglobulinemia: two cases associated with IgG3 kappa cryoglobulin. Am J Kidney Dis 2002; 40: 1091-1096.
72. Kapur U, Barton K, Fresco R et al. Expanding the pathologic spectrum of immunoglobulin light chain proximal tubulopathy. Arch Pathol Lab Med 2007; 131: 1368-1372.
73. Nasr SH, Galgano SJ, Markowitz GS et al. Immunofluorescence on pronase-digested paraffin sections: a valuable salvage technique for renal biopsies. Kidney Int 2006; 70: 2148-2151.
74. Gu X, Barrios R, Cartwright J et al. Light chain crystal deposition as a manifestation of plasma cell dyscrasias: the role of immunoelectron microscopy. Hum Pathol 2003; 34: 270-277.
75. Elliott MR, Cortese C, Moreno-Aspitia A et al. Plasma cell dyscrasia causing light chain tubulopathy without Fanconi syndrome. Am J Kidney Dis 2010; 55: 1136-1141.
76. Said SM, Assaad AM, Cerda J et al. Light chain tubulopathy without Fanconi syndrome. Nephrol Dial Transplant 2006; 21: 3589-3590.
77. Larsen CP, Bell JM, Harris AA et al. The morphologic spectrum and clinical significance of light chain proximal tubulopathy with and without crystal formation. Mod Pathol 2011; 24: 1462-1469.
78. Herrera GA. Renal lesions associated with plasma cell dyscrasias: practical approach to diagnosis, new concepts, and challenges. Arch Pathol Lab Med 2009; 133: 249-267.
79. El Hamel C, Thierry A, Trouillas P et al. Crystal-storing histiocytosis with renal Fanconi syndrome: pathological and molecular characteristics compared with classical myeloma-associated Fanconi syndrome. Nephrol Dial Transplant 2010; 25: 2982-2990.
80. Stokes MB, Aronoff B, Siegel D et al. Dysproteinemia-related nephropathy associated with crystal-storing histiocytosis. Kidney Int 2006; 70: 597-602.
81. Lin J, Markowitz GS, Valeri AM et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 2001; 12: 1482-1492.
82. Alexander MP, Nasr SH, Watson DC et al. Renal crescentic alpha heavy chain deposition disease: a report of 3 cases and review of the literature. Am J Kidney Dis 2011; 58: 621-625.
83. Nasr SH, Markowitz GS, Stokes MB et al. Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immunecomplex glomerulonephritis. Kidney Int 2004; 65: 85-96.
84. Yahata M, Nakaya I, Takahashi S et al. Proliferative glomerulonephritis with monoclonal IgM deposits without Waldenstrom's macroglobulinemia: case report and review of the literature. Clin Nephrol 2012; 77: 254-260.
85. Soares SM, Lager DJ, Leung N et al. A proliferative glomerulonephritis secondary to a monoclonal IgA. Am J Kidney Dis 2006; 47: 342-349.
86. Alpers CE, Tu WH, Hopper J Jr. et al. Single light chain subclass (kappa chain) immunoglobulin deposition in glomerulonephritis. Hum Pathol 1985; 16: 294-304.
87. Pickering MC, D'Agati VD, Nester CM et al. C3 glomerulopathy: consensus report. Kidney Int 2013; 84: 1079-1089.
88. Sethi S, Sukov WR, Zhang Y et al. Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis 2010; 56: 977-982.
89. Zand L, Kattah A, Fervenza FC et al. C3 glomerulonephritis associated with monoclonal gammopathy: a case series. Am J Kidney Dis 2013; 62: 506-514.
90. Bridoux F, Desport E, Fremeaux-Bacchi V et al. Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin Am Soc Nephrol 2011; 6: 2165-2174.
91. Sethi S, Rajkumar SV. Monoclonal gammopathy-associated proliferative glomerulonephritis. Mayo Clin Proc 2013; 88: 1284-1293.
92. Kyle RA, Therneau TM, Rajkumar SV et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354: 1362-1369.